Maravai LifeSciences Holdings, Inc. (MRVI) — Financial statements
Income statement, balance sheet, and cash flow for Maravai LifeSciences Holdings, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 186↓28.3% | 259↓10.3% | 289↓67.3% | 883↑10.5% | 799 | |
| Cost of Revenue | 152↑1.0% | 151↑1.4% | 149↓12.0% | 169↑20.2% | 141 | |
| Gross Profit | 33↓69.2% | 108↓22.7% | 140↓80.4% | 714↑8.4% | 659 | |
| Operating Expenses | ||||||
| R&D Expenses | 23↑21.4% | 19↑11.2% | 17↓5.9% | 18↑20.7% | 15 | |
| General & Administrative Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 171↑6.0% | 162↑6.9% | 151↑17.1% | 129↑29.2% | 100 | |
| Other Expenses | -155↓194.9% | 163↑5023.7% | 3↑140.8% | -8↑30.7% | -11 | |
| Operating Expenses | 40↓88.3% | 344↑100.1% | 172↑22.9% | 140↑34.4% | 104 | |
| Total Costs & Expenses | 192↓61.1% | 495↑54.3% | 321↑3.8% | 309↑26.2% | 245 | |
| Operating Results | ||||||
| Operating Income | -7↑97.1% | -236↓644.5% | -32↓105.5% | 574↑3.5% | 555 | |
| Depreciation & Amortization | 61↑7.0% | 57↑16.6% | 49↑28.0% | 38↑53.9% | 25 | |
| EBITDA | -147↑6.2% | -157↓122.0% | 712↑16.8% | 610↑4.1% | 586 | |
| EBIT | -208↑2.7% | -214↓132.2% | 664↑16.0% | 572↑1.9% | 561 | |
| Interest & Other Income | ||||||
| Net Interest Income | -3↑85.0% | -20↓11.7% | -18↓0.5% | -18↑40.3% | -30 | |
| Interest Income | 24↓12.6% | 27↓1.2% | 28↑1085.9% | 2 | 0.00 | |
| Interest Expense | 27↓43.4% | 48↑3.9% | 46↑124.8% | 20↓32.5% | 30 | |
| Non-Operating Income | 201↑1021.7% | -22↑96.9% | -695↓29940.2% | 2↑136.5% | -6 | |
| Other Income / Expenses | -228↓782.4% | -26↓104.0% | 649↑2955.2% | -23↑4.8% | -24 | |
| Income Before Tax | -235↑10.1% | -261↓142.3% | 618↑12.0% | 551↑3.9% | 531 | |
| Income Tax Expense | -4↓126.5% | -2↓100.2% | 756↑1143.4% | 61↓1.1% | 62 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -231↑11.1% | -260↓87.6% | -138↓128.2% | 491↑4.6% | 469 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -131↑9.7% | -145↓21.7% | -119↓154.1% | 220↑21.0% | 182 | |
| Bottom-Line Net Income | -131↑9.7% | -145↓21.7% | -119↓127.9% | 426↑5.9% | 402 | |
| EPS (Basic) | -0.91↑13.3% | -1.05↓16.7% | -0.90↓153.9% | 1.67↑5.0% | 1.59 | |
| EPS (Diluted) | -0.91↑13.3% | -1.05↓16.7% | -0.90↓153.9% | 1.67↑7.1% | 1.56 | |
| Weighted Average Shares | 145↑5.2% | 138↑4.5% | 132↑0.3% | 132↑14.6% | 115 | |
| Weighted Average Diluted Shares | 145↑5.2% | 138↑4.5% | 132↑0.2% | 132↑8.0% | 122 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.